Drug intelligence / Profile preview

AL2846 + TQB2450

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

AL2846 + TQB2450 is an investigational combination therapy consisting of AL2846, a multi-targeted small molecule receptor tyrosine kinase inhibitor, and TQB2450 (benmelstobart), a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1). This combination is being studied for its potential synergistic effects in treating various advanced cancers, particularly in patients who have progressed on prior immunotherapy treatments.

Other names: benmelstobart + AL2846

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on AL2846 + TQB2450.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL2846 + TQB2450.

Explore the full profile